Zhaoke Ophthalmology Launches Preservative-Free Glaucoma Drug
Zhaoke Ophthalmology Ltd. (HK:6622) has received approval from the National Medical Products Administration for its preservative-free Bimatoprost eye drop, the first of its kind in China. This glaucoma treatment aims to enhance patient comfort and compliance by minimizing long-term side effects associated with preservatives. The launch is significant due to the high prevalence of glaucoma in China, which represents about 25% of the global patient population.
Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Zhaoke Ophthalmology Ltd. has announced the National Medical Products Administration’s approval of its Bimatoprost eye drop, a preservative-free treatment for glaucoma, marking it as China’s first single-dose bimatoprost eye drop without preservatives. The product aims to improve patient comfort and compliance by reducing the long-term side effects associated with preservatives found in other treatments. This development is particularly significant given the high prevalence of glaucoma in China, which accounts for about a quarter of the global patient population.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.